Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

BioVie, Inc. Common Stock (BIVI)

Pharmaceutical Preparations

https://www.bioviepharma.com

BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

680 W NYE LANE, SUITE 201
CARSON CITY, NV

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/14/2014

Market Cap

18,960,693

Shares Outstanding

37,740,000

Weighted SO

37,742,695

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

INZY --.--%

DAWN --.--%

TERN --.--%

ELDN --.--%

HOOK --.--%

XFOR --.--%

ABOS --.--%

MREO --.--%

AMLX --.--%

Beta

1.1790

Last Div

0.0000

Range

2.07-58.2

Chg

0.7299

Avg Vol

81590

Mkt Cap

18960693

Exch

NASDAQ

Country

US

Phone

775 888 3162

DCF Diff

2.8649

DCF

0.1552

Div Yield

0.0000

P/S

0.0000

EV Multiple

0.0799

P/FV

7.3380

Div Yield %

0.0000

P/E

-3.8267

PEG

0.0559

Payout

0.0000

Current Ratio

2.4470

Quick Ratio

2.4470

Cash Ratio

2.4318

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

6459.5055

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0808

ROA

-1.1422

ROE

-2.9442

ROCE

-1.9889

NI/EBT

1.0000

EBT/EBIT

0.9458

EBIT/Rev

0.0000

Debt Ratio

0.2649

D/E

0.4447

LT Debt/Cap

0.0190

Total Debt/Cap

0.3078

Int Coverage

-10.7739

CF/Debt

-4.1854

Equity Multi

1.6788

Rec Turnover

0.0000

Pay Turnover

0.0565

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.7863

FCF/Share

-0.7863

Cash/Share

0.6774

OCF/Sales

0.0000

FCF/OCF

1.0000

CF Coverage

-4.1854

ST Coverage

-4.3759

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

7.3380

P/B

7.3380

P/S

0.0000

P/E

-3.8267

P/FCF

-0.5383

P/OCF

-3.9425

P/CF

-3.9425

PEG

0.0559

P/S

0.0000

EV Multiple

0.0799

P/FV

7.3380

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 01, 01:00 BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 24, 02:26 BioVie Inc. Announces Pricing of Public Offering Seeking Alpha Dec 02, 00:44 BioVie: Update Following Topline Results (Rating Downgrade) Seeking Alpha Dec 02, 00:44 BioVie: Update Following Topline Results (Rating Downgrade) GlobeNewswire Inc. Oct 25, 12:30 Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

Revenue Product Segmentation